KR950013506A - Ibuprofen Liquid - Google Patents

Ibuprofen Liquid Download PDF

Info

Publication number
KR950013506A
KR950013506A KR1019930023940A KR930023940A KR950013506A KR 950013506 A KR950013506 A KR 950013506A KR 1019930023940 A KR1019930023940 A KR 1019930023940A KR 930023940 A KR930023940 A KR 930023940A KR 950013506 A KR950013506 A KR 950013506A
Authority
KR
South Korea
Prior art keywords
sodium
calcium
potassium
phosphate
citrate
Prior art date
Application number
KR1019930023940A
Other languages
Korean (ko)
Inventor
유상현
이정상
류길수
Original Assignee
하기주
주식회사 코오롱
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하기주, 주식회사 코오롱 filed Critical 하기주
Priority to KR1019930023940A priority Critical patent/KR950013506A/en
Publication of KR950013506A publication Critical patent/KR950013506A/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 알칼리성 첨가제를 사용하여 쓴 맛을 제거한 이부프로펜 액제에 관한 것으로, 종래의 수산화알루미늄으로 쓴 맛을 제거한 현탁액제의 제조후 안정성이 적어 보관중 침전이 발생하기 쉬울 뿐만 아니라 제조공정이 복잡하고 복용이 불편한 단점을 극복하였는 바, 약물로서 이부프로펜을 함유하고, 알칼리성 첨가물로는 예를 들면, 탄산수소나트륨, 탄산이수소나트륨, 탄산마그네슘, 탄산알루미늄, 탄산칼슘, 인산수소나트륨, 인산나트륨, 인산알루미늄, 인산칼슘, 인산칼륨, 수산화나트륨, 수산화칼륨, 수산화마그네슘, 스테아린산칼륨, 스테아린산칼슘, 스테아린산마그네슘, 시트르산알루미늄, 시트르산칼슘, 시트르산나트륨, 시트르산칼륨과 같은 무기 알칼리성 첨가제, 또는 α-사이클로덱스트린, β-사이클로덱스트린,-사이클로덱스트린, 사이클로덱스트린 유도체, 리진, 히스티딘, 수크로스 지방산에스테르, 글루코스아민과 같은 유기 단분자, 또는 메타그릴산과 메타크릴산메틸에스테르의 공중합체, 셀룰로스아세테이트프탈레이트, 히드록시프로필메틸셀룰로스프탈레이트, 폴리비닐아세테이트프탈레이트, 카르복시메틸에틸셀룰로스, 히드록시프로필메틸셀루로스아세테이트숙시네이트, 폴리아크릴산유도체, 알진산 등의 나트륨염, 칼슘염, 칼륨염 그리고 디메틸아미노에틸 메타크릴레이트와 메타크릴산메틸에스테르의 공중합체, 폴리비닐피롤리돈 유도체 등에서 선택되는 1종 이상을 함유하며, 여기에 감미제, 향료, 색소, 방부제, 향산화제, 안정화제를 포함하는 통상의 보조제를 첨가하여 쓴 맛이 없고 보관안정성이 뛰어난 새로운 이부프로펜 액제를 제공한다.The present invention relates to an ibuprofen liquid solution from which a bitter taste is removed using an alkaline additive, and is less stable after preparation of a suspension which has been removed from the bitter taste of conventional aluminum hydroxide, so that precipitation does not easily occur during storage, and the manufacturing process is complicated and dosed. Overcoming this uncomfortable disadvantage, it contains ibuprofen as a drug, and as the alkaline additive, for example, sodium bicarbonate, sodium bicarbonate, magnesium carbonate, aluminum carbonate, calcium carbonate, sodium hydrogen phosphate, sodium phosphate, aluminum phosphate , Inorganic alkaline additives such as calcium phosphate, potassium phosphate, sodium hydroxide, potassium hydroxide, magnesium hydroxide, potassium stearate, calcium stearate, magnesium stearate, aluminum citrate, calcium citrate, sodium citrate, potassium citrate, or α-cyclodextrin, β- Cyclodextrin, Cyclodextrins, cyclodextrin derivatives, lysine, histidine, sucrose fatty acid esters, organic monomolecules such as glucoseamine, or copolymers of methacrylic acid and methacrylic acid methyl esters, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, poly Sodium salts such as vinyl acetate phthalate, carboxymethyl ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate, polyacrylic acid derivatives, alginic acid, calcium salts, potassium salts and dimethylaminoethyl methacrylate and methacrylic acid methyl ester It contains at least one member selected from copolymers, polyvinylpyrrolidone derivatives, and the like, and it has no bitter taste and excellent storage stability by adding ordinary supplements including sweeteners, flavorings, pigments, preservatives, oxidizing agents and stabilizers. Provide a new ibuprofen solution.

Description

이부프로펜 액제Ibuprofen Liquid

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (1)

활성성분으로서 이부프로펜 및 알칼리성 첨가물로서 탄산수소나트륨, 탄산이수소나트륨, 탄산마그네슘, 탄산알루미늄, 탄산칼슘, 인산수소나트륨, 인산나트륨, 인산알루미늄, 인산칼슘, 인산칼륨, 수산화나트륨, 수산화칼륨, 수산화마그네슘, 스테아린산칼륨 스테아린산칼슘. 스테아린산마그네슘, 시트르산알루미늄, 시트로산칼슘, 시트르산나트륨, 시트르산칼륨,-사이클로덱스트린, β-사이클로덱스트린,-사이클로덱스트린, 사이클로덱스트린 유도체, 리진, 히스티딘, 수크로스 지방산에스테르, 글로코스아민, 메타크릴산과 메타크릴산메틸에스테르의 공중합체, 셀룰로스아세테이트프탈레이트, 히드록시프로필메틸셀룰로스프탈레이트, 폴리비닐아세테이트프탈레이트, 카르복시메탈에틸셀룰로스, 히드록시프로필메틸셀룰로스아세테이트숙시네이트, 폴리아크릴산유도체 및 알진산의 나트륨염, 칼슘염, 칼륨염, 디메틸아미노 에틸 메타크릴레이트와 메타크릴산메틸에스테르의 공중합체. 폴리비닐피를리돈 유도체에서 선택된 1종 이상의 알칼리성 첨가제를 함유하며, 여기에 감미제, 향료, 색소, 방부제, 항산화제, 안정화제를 포함하는 통상의 보조제를 첨가한 쓴 맛이 없는 이부프로펜 액제.Ibuprofen as an active ingredient and sodium bicarbonate, sodium bicarbonate, magnesium carbonate, aluminum carbonate, calcium carbonate, sodium hydrogen phosphate, sodium phosphate, aluminum phosphate, calcium phosphate, potassium phosphate, sodium hydroxide, potassium hydroxide, magnesium hydroxide Potassium stearate, calcium stearate. Magnesium stearate, aluminum citrate, calcium citrate, sodium citrate, potassium citrate, Cyclodextrin, β-cyclodextrin, Cyclodextrins, cyclodextrin derivatives, lysines, histidines, sucrose fatty acid esters, glycosamines, copolymers of methacrylic acid and methacrylic acid methyl esters, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, carboxy Metal ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate, polyacrylic acid derivatives and sodium salts of calcium alginate, calcium salts, potassium salts, dimethylamino ethyl methacrylate and copolymers of methyl methacrylate. A bitter-flavored ibuprofen solution containing at least one alkaline additive selected from polyvinylpyridone derivatives and to which a conventional adjuvant including sweeteners, flavors, colorants, preservatives, antioxidants and stabilizers is added. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930023940A 1993-11-11 1993-11-11 Ibuprofen Liquid KR950013506A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019930023940A KR950013506A (en) 1993-11-11 1993-11-11 Ibuprofen Liquid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930023940A KR950013506A (en) 1993-11-11 1993-11-11 Ibuprofen Liquid

Publications (1)

Publication Number Publication Date
KR950013506A true KR950013506A (en) 1995-06-15

Family

ID=66825394

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930023940A KR950013506A (en) 1993-11-11 1993-11-11 Ibuprofen Liquid

Country Status (1)

Country Link
KR (1) KR950013506A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100788449B1 (en) * 2005-11-08 2008-01-02 주식회사 일신케미칼 Manufacturing method of dexibuprofen particle for suspension and dexibuprofen suspension
WO2023043207A1 (en) * 2021-09-15 2023-03-23 구주제약주식회사 Pharmaceutical composition with improved stability comprising propionic acid-based drug and stabilizer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100788449B1 (en) * 2005-11-08 2008-01-02 주식회사 일신케미칼 Manufacturing method of dexibuprofen particle for suspension and dexibuprofen suspension
WO2023043207A1 (en) * 2021-09-15 2023-03-23 구주제약주식회사 Pharmaceutical composition with improved stability comprising propionic acid-based drug and stabilizer

Similar Documents

Publication Publication Date Title
JP4624498B2 (en) Taste concealed suspension
EP0654484B1 (en) Pharmaceutical compositions containing inclusion compounds of thioctic or dihydroliponic acid with cyclodextrins and in granule form or in chewable or effervescent tablet form
JP6282644B2 (en) Racecadotril liquid composition
JP2003510243A5 (en)
AU9814398A (en) Ibuprofen composition
ATE138264T1 (en) METHOD FOR PRODUCING MECHANICALLY STABLE, EFFECTIVELY DISSOLVING COMPRIMATS FROM SMALL MOLDED BODY CONTAINING ACTIVE INGREDIENTS
RU2607592C2 (en) New pharmaceutical composition containing nsaid and cyclodextrin
DE69934505D1 (en) IN THE MUND DISSOLVING TABLET CONTAINING A BENZIMIDAZOLE
PT93029A (en) Process for the preparation of a composition containing modified liberty 5- (2,5-DIMETHYLPHENOXY) -2,2-DIMETHYL-PENTANOIC ACID (GEMFIBROZYL)
CA2665611C (en) Stabilized prostaglandin e composition
JPH06211666A (en) Use of clathrate complex of prostaglandin and cyclodextrin in high-liquid pressure treatment of eye
JPH08506119A (en) Recognition activator CI-979HC (1) neutral stabilizing complex
PT93028A (en) A process for the preparation of a composition containing 5- (2,5-DIMETHYL-PHENOXY) -2,2-DIMETHYL-PENTANOIC (GEMFIBROZYL) PROLONGED LIBERATION ACID
JP2009114125A (en) Oral composition
KR950000151A (en) Medicinal composition
BE1001706A3 (en) Solid form of administration, a rapid disintegration, the diclofenac.
KR950013506A (en) Ibuprofen Liquid
PT796238E (en) METHOD OF STABILIZING POLY-INSATURATED FATTY ACIDS AND USING THESE PRODUCTS STABILIZED IN THERAPEUTICS AND COSMETOLOGY
KR20160096199A (en) Racecadotril liquid compositions
JP2018529774A (en) Rinse-free chemical form containing clobetasol propionate and its use in the treatment of psoriasis
JP2973511B2 (en) Oral composition
HU204193B (en) Process for producing gemfibrosil compositions dispersible in water
JPH0616547A (en) Antiphlogistic ophthalmic solution
JP5276591B2 (en) Two-component ophthalmic solution containing pirenoxine
KR910009253A (en) Oral solution

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application